| Ytd | -67.11% | |
| 1y | -41.32% |
| Open | 3.76 | Prev Close | 3.75 | Low | 3.65 | High | 3.77 | Mkt Cap | 284.30M |
| Vol | 445.02K | Avg Vol | 2.61M | EPS | -1.15 | P/E | -3.24 | Forward P/E | -3.84 |
| Beta | 3.05 | Short Ratio | 7.67 | Inst. Own | 89.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-27 | 50-d Avg | 3.75 | 200-d Avg | 7.79 | 1yr Est | 5.29 |
FULC News
New York, New York--(Newsfile Corp. - August 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
New York, New York--(Newsfile Corp. - August 7, 2026) - Kaplan Fox & Kilsheimer LLP is investigating
New York, New York--(Newsfile Corp. - August 5, 2026) - Kaplan Fox & Kilsheimer LLP is investigating
New York, New York--(Newsfile Corp. - August 3, 2026) - Kaplan Fox & Kilsheimer LLP is investigating
New York, New York--(Newsfile Corp. - July 31, 2026) - Kaplan Fox & Kilsheimer LLP is investigating
Fulcrum is trading at a deep discount due to operational distress after the suspension of their main
New York, New York--(Newsfile Corp. - July 29, 2026) - Kaplan Fox & Kilsheimer LLP is investigating
New York, New York--(Newsfile Corp. - July 27, 2026) - Kaplan Fox & Kilsheimer LLP is investigating
New York, New York--(Newsfile Corp. - July 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating
New York, New York--(Newsfile Corp. - July 20, 2026) - Kaplan Fox & Kilsheimer LLP is investigating
New York, New York--(Newsfile Corp. - July 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating
Fulcrum Therapeutics, Inc. stock lost roughly half its value after the FDA flagged class-wide safety
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically
Fulcrum Therapeutics, Inc. stock lost roughly half its value in a single session after the company d
On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restru
NEW YORK--(BUSINESS WIRE)--Shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) saw the stock p
Fulcrum Therapeutics Inc. (NASDAQ:FULC) shares are up on Thursday as the company faces significant c
Fulcrum Therapeutics halts pociredir development after FDA concerns over malignancy risk and begins
Fulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-ris
Analyst rating changes: Stifel and Piper Sandler downgrade FULC, while Truist, Jefferies downgrade T
SEC filings reflected insider equity holdings and awards totaling more than 264,000 shares NEW YORK,
Fulcrum Therapeutics, Inc. guided investors toward a Phase III future for pociredir while a $25.1 mi
Stifel analyst James Condulis downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and
Piper Sandler analyst Edward Tenthoff downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweig
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Fulcrum T
Truist Securities analyst Gregory Renza downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to
Leerink Partners analyst Joseph Schwartz downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outpe
Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, H
Wall Street analysts changed outlook on top names. Read about analyst rating downgrades on ED, FULC,
HC Wainwright & Co. analyst Andrew S. Fein downgrades Fulcrum Therapeutics (NASDAQ:FULC) from
HPE stock jumps 26.55% after reporting strong revenue growth. Top gainers are DXST, MRVL and more. T
Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug
― Company to explore strategic alternatives to maximize stockholder value ―CAMBRIDGE, Mass., June 01
On May 28, 2026, Fulcrum received meeting minutes from recent end-of-phase interactions with the FDA
U.S. stock futures lower on Thursday with Applied Digital Corp. (APLD) falling sharply in pre-market
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen
U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market.
MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information
Fulcrum's new sickle cell trial data show higher hemoglobin levels and no serious safety concern
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.31) per share which met the anal
― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), re
Fulcrum, the AI-powered field process management and data collection platform, today announced it ha
